Clearly, the results of the study “3 drugs to treat covid” Favipiravir-molnupiravir-Paxlovid

Ministry of Public Health (MOPH) confirmed that there is an academic committee on the use of Consider treating people infected with COVID-19 While the results of the study of 3 drugs have different uses according to the symptoms and risk groups of patients, in the future, will “favipiravir” be used or not? depending on academic information and consideration according to the situation

Anutin Charnvirakul Deputy Prime Minister and Minister of Public Health(Minister of the Ministry of Public Health) Said that the Ministry of Health has an academic committee on drug use which is part of the National Communicable Disease Committee by coming out asMedication Guidelinesaccording to medical academic principles for implementation

“Before there was noMolnupiravir, Paxlovid, Remdesivir Everyone was crying for favipiravir. which will be effective or not But the front office confirmed that millions of patients who had taken favipiravir since the onset of symptoms had recovered. or a drug labeled as a specific COVID-19 treatment. When used when symptoms have already escalated It’s not a cure for everyone,” said Anutin.

Dr. Somsak Ankasil, Director-General of the Department of Medical Services, said that Thailand has conducted a comparative study on the use of farvipiravir compared to the control group.COVID-19 patients A total of 93 people in 3 hospitals, all under 60 years of age, had no underlying disease. 25% of patients were obese, with half of them receiving farvipiravir from the first day of symptom onset. No one has ever had COVID-19 and/or have been vaccinated before Everyone had mild or moderate symptoms. There were no patients with severe symptoms in the study program.

Patients were treated and monitored in the hospital. The effectiveness of farvipiravir was measured using the NEWS system, including respiratory rate. blood oxygen saturation oxygen supply, temperature, systolic pressure heart rate level of consciousness which is assessed by medical personnel only

The results showed that farvipiravir significantly improved the severity of symptoms assessed by NEWS in COVID-19 patients faster than the control group. Half improved in 2 days with the drug compared to 14 days in the control group. Farvipiravir did not reduce the number of viruses or make the virus disappear faster. Its effectiveness was not seen when assessing patient symptoms such as fatigue, coughing, and farvipiravir was found to be safe even when symptomatic elevated serum uric acid levels were observed.

Sections with references from 40 multi-institutional research studies in three countries are: United States, Mexico andBrazil There were 1,187 volunteers, 70% of whom were obese, 15% of the elderly, who were taking farvipiravir compared to the control group. using the drug without adjusting the dose according to the patient’s weight Almost all patients received the drug around the 3rd day after onset of symptoms. Approximately one-third of the patients had been vaccinated or had contracted COVID-19 in the past. Self-report via telephone system

The effectiveness of farvipiravir could not be compared in these two studies. Because the details and methods of study are different. Studies in the Americas show late onset of medication in at-risk patients. have severe symptoms and heavy weight without dose adjustment This may result in ineffective treatment or due to evaluation. partly from the feeling of the patient’s symptoms may cause the results of the study to be inconsistent. In Thailand, farvipiravir has been shown to improve symptoms in mild, low-risk COVID-19 patients faster. But the Thai study had no data on the effectiveness of farvipiravir among patients with pneumonia or reduction in mortality.

“In the future, will Favi be used to treat or not? It depends on the brainstorming and consideration of the expert panel. which every time there is a discussion in the group of experts Bring all the information to discuss. Which is now adjusting the way to adjust further Because the situation has been adjusted continuously since the epidemic. It is currently the 24th guideline issued on 11 July 2022.” Dr. Somsak said

while “Molnupiravir” Preliminary analysis data: 762 patients were given molnupiravir, 385 were given molnupiravir and 377 were given placebo. Molnupiravir had been administered 4 tablets twice daily for 5 days. Each person uses 40 pills for treatment. Preliminary results found that reduce the risk of sleep Hospital/death within 29 days of approximately 50% without death in the molnupiravir-treated group.
part “Paxlovid” The manufacturer’s study found that preliminary data were analyzed for 774 people in the Paxlovid group, 389 and placebo, 385 taking two tablets per meal plus one ritonavir tablet taken together. Twice a day for 5 days was found to reduce the risk of hospitalization/death within 28 days by approximately 89% in cases where the drug was administered within 3 days from the onset of symptoms, approximately 85% in cases where the drug was administered within 5 days from the onset of symptoms. There were no deaths in the group taking Paxlovid and ritonavir.

For guidelines for the treatment of COVID-19 patients in Thailand (No. 24, dated 11 July 2022)

1. Patients without symptoms or in good health provide outpatient treatment by isolating at home Provide symptomatic care at the discretion of the physician. Do not give antiviral drugs such as favipiravir. Because most of them disappear on their own. May consider giving Andrographis paniculata at the discretion of the physician

2. Patients with mild symptoms no pneumonia No risk factors for severe disease/comorbid disease and normal lung radiographs. may consider favipiravir The medication should be started as soon as possible. If infection is detected when the patient has symptoms for more than 5 days and the patient is asymptomatic or has mild symptoms, antiretroviral therapy may not be necessary. Because the patient will heal on their own without complications.

3. Patients with mild symptoms but have risk factors for severe disease or have major co-morbidities or patients without risk factors but with mild to moderate pneumonia, still do not need oxygen Only one antiviral drug is recommended, which should be started within 5 days of the onset of symptoms to be effective. If there is one risk factor, the dosing order is molnupiravir. , Remdesivir, Nermatrolvir/ritonavir (Paxlovid) and Favipiravir If there are two or more risk factors, remdesivir is given. or nermatrelvir/ritonavir (Paxlovid) or molnupiravir

and 4. Confirmed patients with pneumonia Severe pneumonia, up to 10 days after symptoms and oxygen exposure Remdesivir is recommended. As soon as possible for 5-10 days depending on clinical symptoms. Patients should be closely monitored for symptoms. concomitant administration of cordicosteroids (corticosteroid)

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.